Lung Cancer

EDU 04 - (INTERACTIVE) Challenges and Controversies of SABR for High Risk Lung Tumors

9/15/2019
4:45 PM - 6:00 PM
Location: Room W190

Session Type: Education
1.25 AMA PRA Category 1 Credits™
1.25 CAMPEP Credits
1.50 MDCB Credits

This educational session will address the current d current knowledge of the role of SABR and hypo-fractionated RT high risk lung lesions, current approach to treat these tumours, available dose-fractionations, and observed toxicity. The challenges in treatment planning will also be discussed - priority coverage of the PTV vs. risk of toxicity, dose volume constraints to be used for planning purposes.

Learning Objectives:

Presentations:

Alina Mihai, MD, MS

Beacon Hospital

Disclosure:
Employment
Beacon Hospital: Radiation Oncologist: Employee

Leadership
Beacon Hospital: Director Oncology Research;
Medisprof Cancer Centre: Associate Medical Director Radiation Oncology: Consultancy role for the Radiation Oncology Dpt

Biography:
Dr Alina Mihai, MD MS
Consultant Radiation Oncologist
Clinical Assistant Professor, UCD School of Medicine
Director of Oncology Research @Beacon Hospital
Associate Medical Director Radiotherapy Medisprof Cancer Centre ,Romania (advisory role)

Dr. Mihai completed her Medical Degree and Specialty in Romania. She was awarded her Master of Science Degree (Radiation Science) in 2006 at the University of Toronto. Her training included Clinical and Research Fellowships in France (University of Rouen) and Canada (University and Toronto and University of Alberta). She joined Beacon Hospital in July 2007.

Dr. Mihai had a pivotal role in the implementation and development of gated and image guided radiotherapy and stereotactic body radiotherapy at Beacon Hospital and Medisprof Cancer Centre. She leads the extracranial SBRT task group at Beacon Hospital.

Her present areas of research and publications include SRS/SBRT for oligometastatic disease, central lung tumors and SBRT in the elderly. She published several peer reviewed articles on these subjects, and was co-author in two chapters of a recently published book on stereotactic radiosurgery and stereotactic ablative radiotherapy. She reported extensively on Beacon’s radiotherapy experience with SRS/SBRT at internationally recognized meetings in Europe and USA. She founded The Annuall Irish SRS/SBRT Symposium in 2002, recognized internationally and attended by more than 120 participants every year. She is Chair of Scientifc Committee . She is also part of the Scientific and Organizing Committee of the Annual Medisprof Best of ASCO-Best of ASTRO meeting,running since 2016.

Under her directorship, the Division of Oncology Research " Beacon hospital increased significantly its activity, currently running 18 national and international multicentric trials. Dr. Mihai is the national PI for three international multicentric trials, and site PI for other five national and international trials.
She is member of several professional organizations including Cancer Trials Ireland, ESTRO, ASTRO, Medisprof Association (Romania)

Presentation(s):

Send Email for Alina Mihai


Assets

EDU 04 - (INTERACTIVE) Challenges and Controversies of SABR for High Risk Lung Tumors



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for EDU 04 - (INTERACTIVE) Challenges and Controversies of SABR for High Risk Lung Tumors